Tailored Care for Patients With CML: Expert Guidance on Therapies to Improve Patient Outcomes

Register now for this CME/CNE/CPE-certified workshop series to hear from experts on individualizing therapy in patients with CML.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Welcome and Introductions
  • Primary Management of Chronic-Phase CML
    • Selecting first-line therapy
    • Monitoring response to TKI therapy
  • Managing Toxicities, Promoting Adherence, and Engaging the Patient
  • Changing Therapy
    • When to consider changing therapy
    • Options after first-line TKI therapy
  • Future Directions
  • Closing Remarks, Question and Answer Session, and Discussion of Available Online Resources and Tools


Date / Time
Event Details


Jorge Cortes, MD

Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia

Goal Statement
The goal of this activity is to improve the competence of all members of the interdisciplinary team in applying the latest guidance and clinical data in the management of individuals with chronic myeloid leukemia.

Target Audience
This program is intended for hematologists/oncologists, pediatric hematologists, pharmacists, nurse practitioners, hematology/oncology nurses, and other healthcare professionals who care for patients with CML.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Compare the mechanisms of actions of available TKIs to block BCR-ABL activity and the associated toxicity profiles of these agents when used to treat patients with CML
  • Increase patient involvement in the initiation of treatment, monitoring of response, managing toxicity, and optimizing adherence
  • Select individualized therapy for patients with chronic-phase CML, considering patient goals, age, medical history, comorbidities, risk score, previous CML treatment, and BCR-ABL1 mutation status
  • Monitor treatment responses and determine optimal timing for therapy changes
  • Evaluate the available evidence, potential predictive factors, patient preferences, and expert recommendations guiding potential therapy discontinuation and treatment-free remissions
  • Optimally sequence second-line, third-line, and later therapeutic strategies to overcome resistance after previous TKI failure


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-222-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.